Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1290252.RAX4CQ89jc6fl597ogSkA_Dvue6HdGalK4Tta9K_0bvO0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1290252.RAX4CQ89jc6fl597ogSkA_Dvue6HdGalK4Tta9K_0bvO0130_assertion type Assertion NP1290252.RAX4CQ89jc6fl597ogSkA_Dvue6HdGalK4Tta9K_0bvO0130_head.
- NP1290252.RAX4CQ89jc6fl597ogSkA_Dvue6HdGalK4Tta9K_0bvO0130_assertion description "[The MEK inhibitor trametinib is globally approved for metastatic melanoma harboring BRAF mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1290252.RAX4CQ89jc6fl597ogSkA_Dvue6HdGalK4Tta9K_0bvO0130_provenance.
- NP1290252.RAX4CQ89jc6fl597ogSkA_Dvue6HdGalK4Tta9K_0bvO0130_assertion evidence source_evidence_literature NP1290252.RAX4CQ89jc6fl597ogSkA_Dvue6HdGalK4Tta9K_0bvO0130_provenance.
- NP1290252.RAX4CQ89jc6fl597ogSkA_Dvue6HdGalK4Tta9K_0bvO0130_assertion SIO_000772 26181424 NP1290252.RAX4CQ89jc6fl597ogSkA_Dvue6HdGalK4Tta9K_0bvO0130_provenance.
- NP1290252.RAX4CQ89jc6fl597ogSkA_Dvue6HdGalK4Tta9K_0bvO0130_assertion wasDerivedFrom befree-2016 NP1290252.RAX4CQ89jc6fl597ogSkA_Dvue6HdGalK4Tta9K_0bvO0130_provenance.
- NP1290252.RAX4CQ89jc6fl597ogSkA_Dvue6HdGalK4Tta9K_0bvO0130_assertion wasGeneratedBy ECO_0000203 NP1290252.RAX4CQ89jc6fl597ogSkA_Dvue6HdGalK4Tta9K_0bvO0130_provenance.